RLMD
Companies
NASDAQ
Relmada Therapeutics Inc.
Health Care
$0.70
+$0.18 (+34.60%)
Price Chart
Overview
About RLMD
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Market Cap
$89.0M
Volume
266.8K
Avg. Volume
270.8K
P/E Ratio
-0.12527363
Dividend Yield
0.00%
Employees
23.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.02
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RLMD shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$89.0M
Volume266.8K
P/E Ratio-0.13
Dividend Yield0.00%
Important Dates
Next Dividend
September 30, 2019Next Earnings
March 28, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025